Schaur R J, Semmelrock H J, Schauenstein E, Kronberger L
J Cancer Res Clin Oncol. 1979 Apr 12;93(3):287-92. doi: 10.1007/BF00964585.
The increase of plasma cortisol in patients with tumors of five different sites compared with a control group of patients with benign surgical diseases amounted to: +39% (breast), +34% (stomach), +86% (intestine), +60% (skin) and +194% (gall bladder). The first detectable increase of cortisol occurred in patients with tumors classified T 2 according to the TNM scheme (+27% above the control). Highly significant increases were observed for T 3 (+82%) and T 4 (+77%) patients. Patients with palpable lymph nodes showed a most significantly increased cortisol mean value compared with patients without palpable lymph nodes. Similarly, the cortisol mean value of patients with distant metastases was significantly higher than the corresponding value of tumor patients without distant metastases. The question remains open, whether the primary site, the extent of the tumor or the occurrence of metastases is the main determinant for the cortisol increase.
与患有良性外科疾病的对照组患者相比,五个不同部位肿瘤患者的血浆皮质醇增加幅度如下:+39%(乳腺)、+34%(胃)、+86%(肠)、+60%(皮肤)和+194%(胆囊)。根据TNM分期系统,皮质醇首次可检测到的增加出现在T2期肿瘤患者中(比对照组高27%)。T3期(+82%)和T4期(+77%)患者的皮质醇显著增加。与未触及淋巴结的患者相比,触及淋巴结的患者皮质醇平均值增加最为显著。同样,有远处转移的患者的皮质醇平均值明显高于无远处转移的肿瘤患者的相应值。肿瘤的原发部位、范围或转移的发生是否是皮质醇增加的主要决定因素,这个问题仍然悬而未决。